Loading...
XNAS
DXCM
Market cap34bUSD
May 20, Last price  
87.34USD
1D
0.44%
1Q
-2.61%
Jan 2017
485.19%
IPO
3,308.39%
Name

Dexcom Inc

Chart & Performance

D1W1MN
P/E
59.44
P/S
8.49
EPS
1.47
Div Yield, %
—
Shrs. gr., 5y
2.25%
Rev. gr., 5y
22.27%
Revenues
4.03b
+11.34%
02,169,7904,627,0009,838,00029,693,00048,631,00076,266,00099,900,000160,000,000259,200,000402,000,000573,300,000718,500,0001,031,600,0001,476,000,0001,926,700,0002,448,500,0002,909,800,0003,622,300,0004,033,000,000
Net income
576m
+6.41%
-30,767,430-46,599,291-45,878,000-55,184,000-53,524,000-55,170,000-44,746,000-54,500,000-29,800,000-22,400,000-57,600,000-65,600,000-50,200,000-127,100,000101,100,000493,600,000154,700,000341,200,000541,500,000576,200,000
CFO
990m
+32.20%
-22,553,785-43,734,840-33,207,000-37,451,000-39,389,000-42,676,000-30,126,000-33,100,0002,400,00023,600,00049,000,00056,200,00092,000,000123,200,000314,500,000475,600,000442,500,000669,500,000748,500,000989,500,000
Earnings
Jul 23, 2025

Profile

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
URL
https://www.dexcom.com/
IPO date
Apr 14, 2005
Employees
7,500
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,033,000
11.34%
3,622,300
24.49%
2,909,800
18.84%
Cost of revenue
2,119,700
3,024,600
2,511,100
Unusual Expense (Income)
NOPBT
1,913,300
597,700
398,700
NOPBT Margin
47.44%
16.50%
13.70%
Operating Taxes
132,800
168,900
49,600
Tax Rate
6.94%
28.26%
12.44%
NOPAT
1,780,500
428,800
349,100
Net income
576,200
6.41%
541,500
58.70%
341,200
120.56%
Dividends
Dividend yield
Proceeds from repurchase of equity
(750,000)
(662,100)
(535,200)
BB yield
2.34%
1.25%
1.11%
Debt
Debt current
1,226,900
21,100
793,100
Long-term debt
1,389,500
2,732,700
1,407,400
Deferred revenue
7,400
19,000
Other long-term liabilities
147,900
59,600
104,400
Net debt
37,000
(8,800)
(274,700)
Cash flow
Cash from operating activities
989,500
748,500
669,500
CAPEX
(236,600)
(364,800)
Cash from investing activities
(207,500)
(507,200)
(521,500)
Cash from financing activities
(734,800)
(318,600)
(552,500)
FCF
1,720,100
329,300
189,900
Balance
Cash
2,579,400
2,724,100
2,456,200
Long term investments
38,500
19,000
Excess cash
2,377,750
2,581,485
2,329,710
Stockholders' equity
1,590,000
1,005,100
468,700
Invested Capital
3,189,400
3,724,500
3,827,100
ROIC
51.50%
11.36%
8.74%
ROCE
40.03%
12.64%
9.27%
EV
Common stock shares outstanding
412,700
425,500
427,500
Price
77.77
-37.33%
124.09
9.58%
113.24
-15.64%
Market cap
32,095,679
-39.21%
52,800,295
9.07%
48,410,100
-15.90%
EV
32,132,679
52,791,495
48,135,400
EBITDA
2,131,000
783,700
554,600
EV/EBITDA
15.08
67.36
86.79
Interest
19,000
20,300
18,600
Interest/NOPBT
0.99%
3.40%
4.67%